Investor Sentiment Mixed as Editas Eyes In Vivo Opportunities Despite a volatile stock performance, Editas Medicine's in vivo gene editing strategy has gained attention. Recent preclinical data highlights potential in liver and stem cell applications, but clinical proof remains years away. Analysts are cautious, citing limited near-term catalysts, while some retail investors speculate on possible M&A activity.56